Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Breast Cancer
100%
Radioimmunotherapy
100%
Androgen Signaling
100%
Pathway Activation
100%
Androgen Receptor
100%
Dihydrotestosterone
100%
Alpha Particles
100%
Human Kallikrein 2
100%
Norgestrel
100%
Radiotherapy
50%
Hormone Stimulation
50%
17β-estradiol
50%
Tumor
25%
Breast Cancer Cell Lines
25%
Breast
25%
Gene Products
25%
Site-specific Delivery
25%
Estrogen
25%
Novel Therapies
25%
Radionuclides
25%
Tumor Tissue
25%
Breast Cancer Model
25%
Xenograft Model
25%
In Vitro Production
25%
Breast Cancer Xenograft
25%
Targeted Radiotherapy
25%
Muscle Uptake
25%
Ther
25%
Competitive Binding
25%
Actinium-225
25%
Androgen Receptor-positive
25%
Androgen Receptor Gene
25%
α-emitter
25%
Breast Cancer Biology
25%
Synthetic Progestogens
25%
Kallikrein-related Peptidases
25%
Medicine and Dentistry
Breast Cancer
100%
Radioimmunotherapy
100%
Androgen Receptor
100%
Kallikrein
50%
Androstanolone
40%
Norgestrel
40%
Radiation Therapy
30%
Neoplasm
20%
Actinium 225
20%
17b-Estradiol
20%
Malignant Neoplasm
10%
In Vitro
10%
Peptidase
10%
Radioisotope
10%
Gestagen
10%
Gene Product
10%
Xenograft
10%
Cancer Pathobiology
10%
Breast Cancer Cell Line
10%
Receptor Gene
10%
Tumor Xenograft
10%
Cancer Model
10%
Binding Competition
10%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Androgen Receptor
100%
Kallikrein
50%
Androstanolone
40%
Norgestrel
40%
Neoplasm
20%
Actinium 225
20%
17b-Estradiol
20%
Malignant Neoplasm
10%
Cancer Model
10%
Peptidase
10%
Progestin
10%
Radioisotope
10%